Andrew Berens
Stock Analyst at Leerink Partners
(1.38)
# 3,411
Out of 4,884 analysts
125
Total ratings
47%
Success rate
-9.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $7.95 | +13.21% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $2.78 | +115.83% | 3 | Apr 2, 2025 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $36.07 | +55.25% | 11 | Sep 27, 2024 | |
| CELC Celcuity | Initiates: Outperform | $29 | $13.79 | +110.30% | 1 | Jul 22, 2024 | |
| BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $128.35 | -24.43% | 24 | May 6, 2024 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $7.58 | +163.85% | 4 | Jan 5, 2023 | |
| AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $69.45 | +13.75% | 12 | Nov 14, 2022 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $36 → $25 | $7.81 | +220.10% | 3 | May 13, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | $40 | $6.56 | +509.76% | 1 | Nov 23, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $67 | $1.48 | +4,427.03% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $140 | $80.48 | +73.96% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $1 | $0.39 | +157.73% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.38 | +1,286.55% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $13.04 | +91.72% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $111.75 | -14.09% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $68.45 | +13.95% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $53.82 | -10.81% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $12.73 | +119.95% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.26 | +2,042.86% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $1.23 | +2,339.02% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $4.87 | +310.68% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.70 | +338.60% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $9.62 | -16.84% | 7 | Jul 14, 2017 |
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $7.95
Upside: +13.21%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $2.78
Upside: +115.83%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $36.07
Upside: +55.25%
Celcuity
Jul 22, 2024
Initiates: Outperform
Price Target: $29
Current: $13.79
Upside: +110.30%
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $128.35
Upside: -24.43%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $7.58
Upside: +163.85%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $69.45
Upside: +13.75%
Cullinan Therapeutics
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $7.81
Upside: +220.10%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.56
Upside: +509.76%
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $1.48
Upside: +4,427.03%
Jun 24, 2025
Maintains: Outperform
Price Target: $125 → $140
Current: $80.48
Upside: +73.96%
Mar 21, 2025
Downgrades: Market Perform
Price Target: $9 → $1
Current: $0.39
Upside: +157.73%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.38
Upside: +1,286.55%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $13.04
Upside: +91.72%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $111.75
Upside: -14.09%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $68.45
Upside: +13.95%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $53.82
Upside: -10.81%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $12.73
Upside: +119.95%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.26
Upside: +2,042.86%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $1.23
Upside: +2,339.02%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $4.87
Upside: +310.68%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $5.70
Upside: +338.60%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $9.62
Upside: -16.84%